急性冠脉综合征患者血浆sCD40L与血清基质金属蛋白酶水平的变化及其意义

目的：观察急性冠脉综合征（ACS）患者可溶性CD40配体（sCD40L）及血清基质金属蛋白酶-9（MMP-9）、血清组织金属蛋白酶抑制物-1（TIMP-1）水平变化及其相关性。方法：采用酶联免疫吸附法测定70例冠心病患者ACS患者35例、稳定型心绞痛（SAP）患者35例]、35例非冠心病患者（正常对照组）sCD40L、MMP-9、TIMP-1的水平。结果：与正常对照组及SAP组比较,ACS组sCD40L（2.73±0.92）μg/ml比（3.05±0.98）μg/ml比（4.72±1.15）μg/ml]、MMP-9（152.38±54.22）ng/ml比（341.12±69.96）ng/ml比（574.2±139.20）ng/ml]水平明显升高（P均〈0.01）,而TIMP-1（415.92±13.96）ng/ml比（249.32±36.80）ng/ml比（172.20±40.10）ng/ml]水平明显降低（P〈0.01）;且MMP-9与sCD40L呈正相关（r=0.42,P〈0.05）。结论：急性冠脉综合征患者可溶性CD40配体、血清基质金属蛋白酶-9水平升高,血清组织金属蛋白酶抑制物-1水平下降提示这两指标与粥样斑块不稳定相关,可作为判断粥样斑块不稳定的血清学指标。

Changes of levels of plasma sCD40L,MMP-9 and TIMP-1 in patients with acute coronary syndrome and their clinical significance

Objective:To investigate changes of levels of soluble CD40 ligand(sCD40L),serum matrix metalloproteinase-9(MMP-9) and serum tissue inhibitor of metalloproteinases-1(TIMP-1) in patients with acute coronary syndrome(ACS) and their correlation.Methods:Enzyme-linked immunosorbent assay was used to measure levels of sCD40L,MMP-9 and TIMP-1 in 70 patients with coronary heart disease(CHD) 35 ACS cases,35 cases with stable angina pectoris(SAP)] and 35 non-CHD patients(normal control group).Results:Compared with no...